Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Inventiva S.A
IVA | US
5.63
USD-0.11
-1.92%
IVA | US
About Inventiva S.A
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/03/2024
As of date
16/04/2026
Close
5.63
Open
5.59
High
5.71
Low
5.52
Inventiva S.A. a clinical-stage biopharmaceutical company focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix France.
View LessIVA | US
Risk
64.4
Sharpe
0.79
Luna's Score
39/100
Recommendation
Sell
Luna says (IVA | US)
What's Working
Low Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
79.0%1 month
64.4%3 months
58.2%6 months
82.9%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
2.10
Debt to equity
-1.15
Debt to assets
0.54
Ent. to EBITDA
-1.34
Ent. to rev.
5.65
PEG
-
Other Fundamentals
EBITDA
-98.36M
MarketCap
296.98M
MarketCap(USD)
296.98M
Div. yield
-
Op. margin
-1.91K
Erngs. growth
-
Rev. growth
-58.70
Ret. on equity
-1.64K
Short ratio
14.15
Short perc.
0.46
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.86
Range1M
1.38
Range3M
2.36
Volumes: Market Activity
Rel. volume
1.24
Price X volume
3.19M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.34 | - | Cheaper |
| Ent. to Revenue | 5.65 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.10 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 58.18 | - | Lower Risk |
| Debt to Equity | -1.15 | -1.23 | Cheaper |
| Debt to Assets | 0.54 | 0.25 | Expensive |
| Market Cap | 296.98M | - | Emerging |
